NPPB and atrial fibrillation: This result is supported by the primary results of the EMPAG-HF trial, which presented a statistically significant decrease in NT-proBNP.18 However, the impact on atrial fibrillation burden needs further analysis on a larger cohort with longer follow up and appropriate statistical power.